The Current Place of Tranexamic Acid in the Elective Hip Arthroplasty



Rok publikování 2022
Druh Článek ve sborníku
Konference Noninvasive methods in cardiology 2022
Fakulta / Pracoviště MU

Lékařská fakulta

Klíčová slova Elective Hip Arthroplasty; Tranexamic Acid
Popis The total hip arthroplasties (???) are associated with perioperative blood losses exceeding 500 mL, some studies claim average blood losses of up to 1500Ml [1]. Blood loss volumes are certainly strongly dependent on the chosen surgical approach and technique. Approximately 30% of patients that undergo elective hip replacement receive at least one blood unit in postoperative care [2]. Reducing blood losses has a beneficial impact on recovery time, length of stay, and health economics. In the last decade, there has been an increasing interest in the efficacy of tranexamic acid (TXA) in orthopaedics and especially in elective major joint replacements. Highlighted advantages of the TXA in hip replacement surgery are the systemic or local prevention of hemorrhage and the prevention of heterotopic ossification formation. This paper presents an overview of our current understanding of the use of TXA in elective hip replacement.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info